Hepatitis B Clinical Study Pipeline

Golden Biotechnology Corporation (GBC) cooperated with Chung Shan Medical University Hospital to initiate a phase II clinical trial, “A randomized, double-blind, dosing-ranging, placebo-controlled trial of Antroquinonol in patients with chronic hepatitis B” (Proof of concept, PoC study). The effectiveness verification of the phase II trial is approved by TFDA in May, 2018. GBC estimates to complete the study in 2019Q1.

Atopic Dermatitis Clinical Study Pipeline

Golden Biotechnology Corporation (GBC) cooperated with Chung Shan Medical University Hospital to initiate a phase II clinical trial, “A randomized, double-blind, placebo-controlled trial of Antroquinonol in patients with atopic dermatitis”. The phase II trial (proof of concept, PoC study) is approved by TFDA in July, 2018. GBC estimates to complete the study in 2019Q1.